CYP2B6 polymorphisms and nevirapine and efavirenz DILI

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 2037卷 / 1期
关键词：
D O I：
10.1007/s40278-024-71697-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4 / 4
相关论文
共 50 条
  • [31] Identification of novel cyp2b6 haplotypes in individuals with impaired metabolism of efavirenz
    Wang, J
    Sönnerborg, A
    Rane, A
    Lundgren, S
    Stahle, L
    Ingelman-Sundberg, M
    DRUG METABOLISM REVIEWS, 2005, 37 : 75 - 75
  • [32] CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
    Griesel, Rulan
    Maartens, Gary
    Chirehwa, Maxwell
    Sokhela, Simiso
    Akpomiemie, Godspower
    Moorhouse, Michelle
    Venter, Francois
    Sinxadi, Phumla
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E3902 - E3909
  • [33] Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?
    Margalida Rotger
    Amalio Telenti
    European Journal of Clinical Pharmacology, 2008, 64 : 335 - 336
  • [34] Screening for CYP2B6 polymorphisms in the Roma (Gypsy) population
    Kuhanec, A.
    Tomas, Z.
    Juric, T. Skaric
    Narancic, N. Smolej
    Janicijevic, B.
    Petranovic, M. Zajc
    Salihovic, M. Pericic
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 684 - 684
  • [35] Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways.
    Lamson, M
    MacGregor, T
    Riska, P
    Erickson, D
    Maxfield, P
    Rowland, L
    Gigliotti, M
    Robinson, P
    Azzam, S
    Keirns, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 137 - 137
  • [36] The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
    Ward, BA
    Gorski, JC
    Jones, DR
    Hall, SD
    Flockhart, DA
    Desta, Z
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (01): : 287 - 300
  • [37] Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals
    Heil, Sandra G.
    van der Ende, Marchina E.
    Schenk, Paul W.
    van der Heiden, Ilse
    Lindemans, Jan
    Burger, David
    van Schaik, Ron H. N.
    THERAPEUTIC DRUG MONITORING, 2012, 34 (02) : 153 - 159
  • [38] Exploring CYP2B6 activity by measuring the presence of nevirapine hydroxy metabolites in plasma
    Mustafa, Suzana
    Hassan, Norul Badriah
    Tan, Soo Choon
    Mustafa, Mahiran
    Ab Rahman, Ahmad Kashfi
    Low, Lee Lee
    Wan Yusuf, Wan Nazirah
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2016, 46 (06) : 1875 - 1881
  • [39] Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen
    Kassogue, Yaya
    Diakite, Brehima
    Maiga, Mamoudou
    Kassogue, Oumar
    Konate, Issa
    Tamboura, Kadidiatou
    Diarra, Fousseyni
    Diarra, Zoumana
    Sawadogo, Mahamadou Karamoko
    Goita, Yaya
    Sissoko, Sidi Boula
    Sissoko, Adama Seydou
    Guirou, Nouhoum
    Dehbi, Hind
    Nadifi, Sellama
    Bah, Sekou
    Traore, Cheick Bougadari
    Kamate, Bakarou
    Dao, Sounkalo
    Dolo, Guimogo
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (06): : 219 - 225
  • [40] CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
    Kwara, Awewura
    Lartey, Margaret
    Sagoe, Kwamena W. C.
    Kenu, Ernest
    Court, Michael H.
    AIDS, 2009, 23 (16) : 2101 - 2106
12345